Loading clinical trials...
Loading clinical trials...
An Observer-blinded, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac COVID-19 Vaccines or One Formulation of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) Determined in a lead-in Formulation Finding in Healthy Adults.
Conditions
Interventions
ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)
CoronaVac (Sinovac Biotech)
+1 more
Locations
3
Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio de Grande Do Sul, Brazil
Hospital Gloria D'or
Rio de Janeiro, Rio de, Brazil
Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN)
Natal, Rio Grande do Norte, Brazil
Start Date
December 1, 2021
Primary Completion Date
April 1, 2022
Completion Date
April 1, 2022
Last Updated
October 21, 2021
NCT04525716
NCT03188796
NCT06355232
NCT05191420
NCT04611243
NCT04678193
Lead Sponsor
D'Or Institute for Research and Education
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions